LMR Master Fund’s Theriva Biologics TOVX Stock Holding History

LMR Master Fund’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	$202K	Buy	+15	New	+$189K	0.02%	316

Other funds holding TOVX

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

BGA

Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

LMR Master Fund's TOVX Position: Q4 2013 in Review

LMR Master Fund opened a new position in Theriva Biologics (TOVX) in Q4 2013: 15 shares worth $202K. The stake represents 0.02% of the portfolio and ranks #316 among its holdings.

23 funds tracked by Wall St. Rank hold TOVX as of Q4 2013.

LMR Master Fund held 15 shares of Theriva Biologics worth $202K as of Q4 2013.
Theriva Biologics was a new LMR Master Fund position in Q4 2013.
Theriva Biologics made up 0.02% of LMR Master Fund's portfolio in Q4 2013, its #316 holding.
23 funds tracked by Wall St. Rank held Theriva Biologics as of Q4 2013.

Based on LMR Master Fund's 13F filing for Q4 2013, filed 14 Feb 2014.